<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-107269</identifier>
<setSpec>0214-1221</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Intestinal transplant: in what phase are we?</dc:title>
<dc:description xml:lang="en">Objective. To analyze the evolution of Small Bowel Transplantation program since the beginning of the program. Matherial and methods. All children who underwent intestinal transplantation between 1997 and 2009 were retrospectively reviewed: epidemiological data, status before transplant, surgical technique, immunosupression, results, survival and long. term quality of life were analysed. Results. Fifty-two intestinal transplants were performed in 46 children (20 isolated bowel, 20 combined liver and intestine, and 12 multivisceral); median age was 32m (range 7m-19a); weight 12,3 kg (range3,9-60); 31 had short gut syndrome, 8 dismotility, 5 intractable diarrhea, and two were miscellaneous. Intestinal adaptation was initially attempted in 26 patients, without success, 20 were directly listed for transplant. The modality of transplant was modified in 17 while listed. Baseline immune supression consisted of tacrolimus and steroids, although 5 required conversion to Sirolimus later. Six died during the first month, due to sepsis/multiorganic failure (poor status at transplant);13 died during the long-term follow-up. Acute rejection was seen in 20,chronic rejection in 3, PTLD in 8 (6 died) and GVHD in 5 patients (3died). Overall survival after 5 years of follow-up is 65,2 % (51,7% for (..) (AU)</dc:description>
<dc:creator>Ramos, E</dc:creator>
<dc:creator>Gámez, M. L</dc:creator>
<dc:creator>Encinas, J. L</dc:creator>
<dc:creator>Tovar, J. A</dc:creator>
<dc:creator>Molina, M</dc:creator>
<dc:creator>López Santamaría, M</dc:creator>
<dc:creator>Martínez, L</dc:creator>
<dc:creator>Murcia, J</dc:creator>
<dc:creator>Frauca, E</dc:creator>
<dc:creator>Leal, N</dc:creator>
<dc:creator>Sarriá, J</dc:creator>
<dc:creator>Andrés Moreno, A. M</dc:creator>
<dc:creator>Hernández, F</dc:creator>
<dc:creator>Martínez-Ojinaga, E</dc:creator>
<dc:creator>Delgado, M</dc:creator>
<dc:creator>Prieto, G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Analizar la evolución del trasplante intestinal (TI) desde el inicio del programa .Material y métodos. Estudiamos retrospectivamente todos los niños con TI (1997-2009): epidemiología, situación previa, técnica quirúrgica, inmunosupresión, resultados, supervivencia y calidad de vida .Resultados. Realizamos 52 TI (20 intestinal aislado, 20 hepatointestinal, 12 multiviscerales) en 46 niños, edad mediana 32m (rango7m-19a); peso 12,3 kg (rango 3,9-60); 31 tenían intestino corto, 8 dismotilidad, 5 diarrea intratable y 2 misceláneos. Veintiséis se intentaronadaptar inicialmente, 20 se incluyeron directamente como candidatos. La modalidad de trasplante se modificó durante su espera en 18. Todos recibieron tacrolimus y corticoides requiriendo 5 conversión a sirolimus posteriormente. Seis fallecieron el primer mes por sepsis/fallo multiorgánico (mala situación basal); 13 fallecieron tardíamente; observamos rechazo agudo en 20, rechazo crónico en 3, síndrome linfoproliferativo en 8 (fallecieron 6), y EICH en 5 (fallecieron 3). La supervivencia tras 5 años es del 65,2 % (51,7% el injerto). Desde 2006-2008,la supervivencia a los 6m, 1 y 3 años del paciente/injerto es 88,7/84,1,81,2/81,2 y 81,2/71,1%, respectivamente. Tras un seguimiento medio de 39 ± 29 meses, todos los pacientes vivos (n=27, 59%) son autónomos digestivos (70% ya sin estoma), están escolarizados, con mínimosingresos y buena calidad de vida. Conclusiones. El TI se afianza como alternativa de tratamiento en (..) (AU)</dc:description>
<dc:source>Cir Pediatr;23(3): 177-183, jul. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-107269</dc:identifier>
<dc:title xml:lang="es">Trasplante intestinal: ¿en qué fase estamos?</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d13158^s22009</dc:subject>
<dc:subject>^d7573^s22009</dc:subject>
<dc:subject>^d30103^s22073</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d33809^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30401^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7585^s22070</dc:subject>
<dc:type>article</dc:type>
<dc:date>201007</dc:date>
</metadata>
</record>
</ibecs-document>
